Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
ResMed's Capital Expenditure for the
three
months ended in Sep. 2024 was $-19.61 Mil. Its Revenue for the
three
months ended in Sep. 2024 was $1,224.51 Mil.
Hence, ResMed's Capex-to-Revenue for the
three
months ended in Sep. 2024 was 0.02.
ResMed Capex-to-Revenue Historical Data
The historical data trend for ResMed's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ResMed's Capex-to-Revenue
For the Medical Instruments & Supplies subindustry, ResMed's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ResMed's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where ResMed's Capex-to-Revenue falls into.
ResMed Capex-to-Revenue Calculation
ResMed's Capex-to-Revenue for the fiscal year that ended in Jun. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ResMed (NYSE:RMD) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
ResMed Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of ResMed's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RMD has been successfully added to your 